13:42 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Organ transplant rejection Mouse studies suggest inhibiting CXCL13, CD40L and ICOSLG, which play roles in B cell maturation and activation, could help treat antibody-mediated lung transplant rejection. In a mouse model of antibody-mediated lung...
23:20 , Jul 11, 2017 |  BioCentury  |  Emerging Company Profile

Complementary ALS play

Alsonex Pty. Ltd. is targeting a central component of the complement cascade to quell neuroinflammation in amyotrophic lateral sclerosis without excessively dampening the immune system. That mechanism could slow disease progression and improve life expectancy...
07:00 , Sep 12, 2016 |  BioCentury  |  Strategy

Dealing Denali

Denali Therapeutics Inc .'s recent unveiling of 11 deals provides the first glimpse of how the company plans to deploy its nearly $350 million war chest to target neurodegenerative diseases. The company has previously said...
01:31 , Mar 30, 2016 |  BC Extra  |  Clinical News

ALS non-profit, Denali aim to identify new endpoints

Neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) partnered with the ALS Therapy Development Institute to evaluate and analyze data collected by the institute under its Precision Medicine Program to identify new clinical...
08:00 , Jan 30, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Amgen's IBD gene hunt Amgen Inc. is teaming up with researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard to find new targets in inflammatory bowel disease. The partners hope an...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

Neurimmune, ALS TDI deal

Neurimmune and the not-for-profit's Anelixis Therapeutics LLC virtual biotech subsidiary partnered to develop preclinical human antibodies from Neurimmune that target misfolded superoxide dismutase 1 (SOD1) to treat amyotrophic lateral sclerosis (ALS). The not-for-profit said the...
07:00 , Oct 10, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Focusing the BRAIN The NIH 's BRAIN initiative has developed a road map for its near-term research priorities, chief among which is conducting a census of brain cells. Whether the ambitious, decades-long project will be...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Anida, ALS Therapy Development Institute (ALS TDI) deal

The not-for-profit partnered with Anida to evaluate Anida's preclinical compound, neuroprotectin D1 ( NPD1 ), in superoxide dismutase 1 (SOD1) mice as a potential treatment for amyotrophic lateral sclerosis (ALS). ALS TDI said it will...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Clinical News

Gilenya: Phase IIa start

In May, the ALS Therapy Development Institute will begin a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 0.5 mg oral Gilenya fingolimod once daily for about 28 days in about 30 ALS patients. The...
08:00 , Jan 21, 2013 |  BioCentury  |  Product Development

Solving the ALS maze

Three companies with Phase II data for amyotrophic lateral sclerosis believe they have identified at least two ways to improve the odds of clinical success, even though the disease has poorly understood biology, heterogeneous presentation...